Steelers defensive end Yahya Black is putting AAMDSIF in the spotlight—add your support with a gift today.
Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile. Treatment with the hepcidin mimetic rusfertide continued to demonstrate sustained hematocrit control below 45% and high…
Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…
This guide provides important information about bone marrow and stem cell transplantation
This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part
A list of organizations & programs that may provide financial resources & other assistance
Bone Marrow Failure Disease Research Summaries for Patients from the 2020 American Hematology Society Annual Meeting
Summary for patients from the seventh International Bone Marrow Failure Disease Scientific Symposium
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure
